Clinical trials with hypoxic cell sensitizers: Time to retrench or time to push forward?

Raul C. Urtasun, C. Norman Coleman, Todd H. Wasserman, T. L. Phillips

Research output: Contribution to journalArticle

Abstract

Results of world-wide clinical trials with misonidazole are discussed. An attempt is made to assess the reasons for the lack of positive results and the cost-benefit analysis is critically reviewed. The data on the clinical investigations of the second generation misonidazole analogues SR-2508 and RO-03-8799 are presented. Emphasis is placed on future work such as tumor selection for clinical trials, reduction of drug toxicity and methods to increase the drug radiosensitizing properties. Because of the large amount of knowledge, experience, productivity and good scientific clinical data accummulated with nitroimidazoles over the past five years, it is recommended that this is the time to push forward with the work on the newest, more efficient compounds.

Original languageEnglish (US)
Pages (from-to)1691-1696
Number of pages6
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume10
Issue number9
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Misonidazole
Etanidazole
drugs
cost benefit analysis
Clinical Trials
Radiation-Sensitizing Agents
Nitroimidazoles
Drug-Related Side Effects and Adverse Reactions
productivity
toxicity
Cost-Benefit Analysis
tumors
analogs
Neoplasms

Keywords

  • Clinical trials
  • Radioprotectors
  • Radiosensitizers

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Clinical trials with hypoxic cell sensitizers : Time to retrench or time to push forward? / Urtasun, Raul C.; Coleman, C. Norman; Wasserman, Todd H.; Phillips, T. L.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 10, No. 9, 1984, p. 1691-1696.

Research output: Contribution to journalArticle

Urtasun, Raul C. ; Coleman, C. Norman ; Wasserman, Todd H. ; Phillips, T. L. / Clinical trials with hypoxic cell sensitizers : Time to retrench or time to push forward?. In: International Journal of Radiation Oncology, Biology, Physics. 1984 ; Vol. 10, No. 9. pp. 1691-1696.
@article{35594b101ab643bb887a9ac755b697d2,
title = "Clinical trials with hypoxic cell sensitizers: Time to retrench or time to push forward?",
abstract = "Results of world-wide clinical trials with misonidazole are discussed. An attempt is made to assess the reasons for the lack of positive results and the cost-benefit analysis is critically reviewed. The data on the clinical investigations of the second generation misonidazole analogues SR-2508 and RO-03-8799 are presented. Emphasis is placed on future work such as tumor selection for clinical trials, reduction of drug toxicity and methods to increase the drug radiosensitizing properties. Because of the large amount of knowledge, experience, productivity and good scientific clinical data accummulated with nitroimidazoles over the past five years, it is recommended that this is the time to push forward with the work on the newest, more efficient compounds.",
keywords = "Clinical trials, Radioprotectors, Radiosensitizers",
author = "Urtasun, {Raul C.} and Coleman, {C. Norman} and Wasserman, {Todd H.} and Phillips, {T. L.}",
year = "1984",
doi = "10.1016/0360-3016(84)90530-3",
language = "English (US)",
volume = "10",
pages = "1691--1696",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Clinical trials with hypoxic cell sensitizers

T2 - Time to retrench or time to push forward?

AU - Urtasun, Raul C.

AU - Coleman, C. Norman

AU - Wasserman, Todd H.

AU - Phillips, T. L.

PY - 1984

Y1 - 1984

N2 - Results of world-wide clinical trials with misonidazole are discussed. An attempt is made to assess the reasons for the lack of positive results and the cost-benefit analysis is critically reviewed. The data on the clinical investigations of the second generation misonidazole analogues SR-2508 and RO-03-8799 are presented. Emphasis is placed on future work such as tumor selection for clinical trials, reduction of drug toxicity and methods to increase the drug radiosensitizing properties. Because of the large amount of knowledge, experience, productivity and good scientific clinical data accummulated with nitroimidazoles over the past five years, it is recommended that this is the time to push forward with the work on the newest, more efficient compounds.

AB - Results of world-wide clinical trials with misonidazole are discussed. An attempt is made to assess the reasons for the lack of positive results and the cost-benefit analysis is critically reviewed. The data on the clinical investigations of the second generation misonidazole analogues SR-2508 and RO-03-8799 are presented. Emphasis is placed on future work such as tumor selection for clinical trials, reduction of drug toxicity and methods to increase the drug radiosensitizing properties. Because of the large amount of knowledge, experience, productivity and good scientific clinical data accummulated with nitroimidazoles over the past five years, it is recommended that this is the time to push forward with the work on the newest, more efficient compounds.

KW - Clinical trials

KW - Radioprotectors

KW - Radiosensitizers

UR - http://www.scopus.com/inward/record.url?scp=0021205184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021205184&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(84)90530-3

DO - 10.1016/0360-3016(84)90530-3

M3 - Article

C2 - 6237083

AN - SCOPUS:0021205184

VL - 10

SP - 1691

EP - 1696

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 9

ER -